Suchergebnisse - "San-Miguel, Jesús F"

PubPharm (492)

1

Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

enthalten in: Blood cancer discovery | 2024

von Ghobrial, I. | Gormley, N. | Kumar, S. | +28

2

Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma : Results From the Phase II MajesTEC-1 Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Martin, T. | Moreau, P. | Usmani, S. | +20

3

Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling

enthalten in: Haematologica | 2024

von Cardona-Benavides, I. | Misiewicz-Krzeminska, I. | Rojas, E. | +13

4

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

enthalten in: Blood | 2024

von Guerrero, C. | Puig, N. | Cedena, M. | +20

CommentIn: Blood. 2024 Feb 15;143(7):564-566. - PMID 38358852

5

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma : results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

enthalten in: Haematologica | 2024

von González-Calle, V. | Rodríguez-Otero, P. | Sureda, A. | +17

6

Myeloma evades T cell-engaging therapies

enthalten in: Nature cancer | 2023

von Paiva, B. | San-Miguel, J.

7

Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma

enthalten in: The Lancet. Haematology | 2023

von Rodriguez-Otero, P. | Tamariz, L. | San-Miguel, J.

CommentOn: Lancet Haematol. 2023 Oct;10(10):e801-e812. - PMID 37793771

8

Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients

enthalten in: Haematologica | 2023

von Puertas, B. | González-Calle, V. | Sureda, A. | +24

9

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

enthalten in: Nature communications | 2023

von Botta, C. | Perez, C. | Larrayoz, M. | +40

10

Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel

enthalten in: Blood cancer discovery | 2023

von Paiva, B. | Manrique, I. | Rytlewski, J. | +12

CommentIn: Blood Cancer Discov. 2023 Sep 1;4(5):346-348. - PMID 37655402

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[50]